A Case Series of Culturally-adapted CBTp for Black People in the UK

July 8, 2026 updated by: Peter Panayi, University of Manchester

Culturally-adapted Cognitive-behavioural Therapy for Black Sub-Saharan African and Caribbean People Experiencing Psychosis: A Case Series

The goal of this case series study is to learn if culturally-adapted cognitive-behavioural therapy is practical, acceptable and safe among Black Sub-Saharan African and Caribbean people experiencing psychosis. The main question it aims to answer is:

Is culturally-adapted CBT for psychosis feasible, acceptable to and safe for Black Sub-Saharan African and Caribbean people experiencing psychosis?

Participants will be asked to:

  • Answer some questionnaires about how things are at the moment
  • Attend up to 16 sessions of therapy
  • Answer the same questionnaires to see what has changed, if anything
  • Complete a semi-structured interview about their expectations and experience of therapy

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

6

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United Kingdom
      • Manchester, United Kingdom
        • Recruiting
        • Greater Manchester Mental Health NHS Foundation Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Service users who identify as Black British, Black Caribbean, Black African, African-Caribbean or Mixed African/Caribbean with at least one parent and/or grandparent born in a Sub-Saharan African or Caribbean country
  • People with a current ICD-10 schizophrenia spectrum disorder diagnosis, or who are currently receiving or have received support from an Early Intervention in Psychosis team
  • 16 years or older
  • Sufficient understanding of English to complete study measures and engage with CBTp

Exclusion Criteria:

  • Current, primary diagnosis of substance use disorder
  • Organic aetiology of psychosis
  • Lacking capacity to provide full informed consent
  • Currently experiencing a mental health crisis (i.e., are open to a home-based treatment team; are currently under Section of the Mental Health Act or have been under Section in the past 3 months) or immediate high risk to self or others (i.e., current suicidal intent or plans; unmanaged and intense non-suicidal self-injury)
  • Currently receiving CBTp or received CBTp within the preceding 3 months
  • Unwilling to participate in culturally-adapted CBTp

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Therapy
Behavioral: Culturally-adapted cognitive-behavioural therapy
Cognitive-behavioural therapy for psychosis culturally-adapted for Black Sub-Saharan African and Caribbean people using a dedicated, integrated treatment manual

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Semi-structured qualitative interview: Service user acceptability
Time Frame: End of therapy (16 weeks)
Service user satisfaction as assessed by qualitative interview.
End of therapy (16 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Working Alliance Inventory-Short Form Revised
Time Frame: End of therapy (16 weeks)
Acceptability measured sessionally using the Working Alliance Inventory-Short Form Revised (Hatcher & Gillaspy, 2006)
End of therapy (16 weeks)
Adverse Events Checklist
Time Frame: Each therapy session (16 weeks)
Safety monitored sessionally using an Adverse Events Checklist developed for this study
Each therapy session (16 weeks)
Subjective Experience of Psychosis Scale
Time Frame: End of therapy (16 weeks)
Subjective distress measured by the Subjective Experience of Psychosis Scale (Haddock et al., 2011)
End of therapy (16 weeks)
Questionnaire about the Process of Recovery
Time Frame: End of therapy (16 weeks)
Perceived recovery measured by the Questionnaire about the Process of Recovery (Law et al., 2014)
End of therapy (16 weeks)
Depression, Anxiety and Stress Scales
Time Frame: End of therapy (16 weeks)
Emotional wellbeing measured by the Depression, Anxiety and Stress Scales (Lovibond & Lovibond, 1995)
End of therapy (16 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Manchester

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 24, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

September 30, 2025

First Submitted That Met QC Criteria

November 18, 2025

First Posted (Actual)

November 26, 2025

Study Record Updates

Last Update Posted (Actual)

July 10, 2026

Last Update Submitted That Met QC Criteria

July 8, 2026

Last Verified

November 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NHS002287

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe